The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.
Anticipating changes within the US healthcare landscape after Donald J. Trump becomes president next week, The American Society of Clinical Oncology (ASCO) has released guiding principles that the new Congress and administration can use to ensure that the focus does not waiver from the patient.
The primary emphasis of these principles is to ensure access to healthcare and adequate insurance to improve outcomes among those diagnosed with cancer. Pointing out that uninsured and underinsured families often decide to forego cancer care because of the impending out-of-pocket cost burden, ASCO thinks that this is a form of avoidable stress for patients and their families. “This circumstance also increases overall expenses for all Americans,” the brief states.
With this in mind, the following principles were created so policymakers can protect the interests of patients with cancer:
ASCO President Daniel F. Hayes, MD, FACP, FASCO, said, “As a new administration and Congress commence their important work, we will continue to advocate for policies that reflect the current realities of today’s cancer care and ensure that patients with cancer receive the full range of services they critically need.”
The 20 million patients and families who gained health insurance between 2010, when the Affordable Care Act (ACA) was passed, through 2016, have reason to be worried as the Republican party initiates the ACA repeal process. Patients have been asking tough questions to politicians, including House Speaker Paul Ryan, about the future of their healthcare. The Hill reports that a cancer patient—who’s Republican and was initially opposed to the ACA—told Ryan during a CNN town hall meeting, “thanks to the [ACA} I am standing her today alive. Why would you repeal [it] without a replacement?”
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More